

contacting Stephen Finley, Ph.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804 (telephone 301/496-7735, ext. 215; fax 301/402-0220). A signed Confidential Disclosure Agreement will be required to receive a copy of the patent applications.

A Method for Imaging Nicotinic Acetylcholinergic Receptors in the Brain Using Radiolabeled Pyridyl 7-Azabicycloheptanes

ED London, AS Kimes, A Horti, RF Dannals, M Kassiou (NIDA) Serial No. 08/642,636 filed 06 May 96

The current invention embodies the use of radiolabeled analogs of epibatidine to noninvasively image and quantify levels of nicotinic acetylcholine receptors in a living mammalian brain, using Positron Emission Tomography or other nuclear medicine methods. As nicotinic acetylcholine receptors have been implicated in various neuropathological and physiological disorders, including Alzheimer's disease, the invention may represent a powerful new method for the noninvasive diagnosis of Alzheimer's disease and other disorders. In addition, the method embodied in the invention may prove valuable for use in monitoring the progression of various disorders and in determining the efficacy of drug therapy protocols used in the treatment of these disorders. (portfolio: Central Nervous System—Diagnostics, in vivo)

Identification of an Allelic Ser₈₅₇-Asn₈₅₇ Variation of the Human Delayed Rectifier Potassium Channel DRK1 (KCNB1 locus)

D Goldman, AW Bergen, CM Mazzanti, S Michelini (NIAAA) Serial No. 60/020,348 filed 24 Jun 96

The DRK1 potassium channel is voltage sensitive such that as phosphorylation of the protein is increased the current is reduced, thereby increasing the cell's excitability. The amino- and carboxyl-terminal regions of DRK1 are located in the cytoplasm. A new, but naturally occurring substitution of the human delayed rectifier potassium channel DRK1 (KCNB1 locus) was mapped to chromosome 20q13.2. The nonconservative substitution occurs at position 857 in the carboxy terminal region of the protein. Transmembrane sequences of the rat and human DRK1 have been shown elsewhere to be identical, but have different pharmacological and conductance differences. The substitution of

cytoplasmic serine to asparagine may effectively remove a possible phosphorylation site which could result in increased excitability of the cell or effect the function of the protein by altering the conformation, thereby accounting for the pharmacological and conductance changes. The DRK1 was mapped to the same locus as the dominantly inherited EEG trait difference, a low voltage alpha trait difference (20q13.3-13.3), but no correlation could be found between the substitution and the low voltage alpha trait. (portfolios: Central Nervous System—Therapeutics, psychotherapeutics; Central Nervous System—Diagnostics; Central Nervous System—Research Materials).

Dated: October 28, 1996.

Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.

[FR Doc. 96-28274 Filed 11-1-96; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Notice of Meeting

Notice is hereby given of the meeting of the National Cancer Institute Board of Scientific Advisors Clinical Trials Review Working Group, November 25-26, 1996 at the Doubletree Hotel, Rockville, Maryland.

The meeting will be open to the public on November 25, 1996 from 8 am to 2 pm for discussions of methods to maximize the exchange of information and collaboration between laboratory and clinical scientists and between the pharmaceutical industry and NCI funded researchers, and on November 26 from 8 am to 8:30 am for introductory remarks and welcome.

The meeting will be closed to the public on November 25, 1996 from 2 pm to approximately 6 pm and on November 26 from 8:30 am to approximately 6 pm for discussion of confidential issues relating to the review, discussion and evaluation of individual programs and projects conducted by the Clinical Trials Extramural Program. These discussions will reveal confidential trade secrets or commercial property such as patentable material, and personal information including consideration of personnel qualifications and performance, the competence of individual investigators and similar matters, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Information pertaining to the meeting may be obtained from Dr. John S. Cole, III, Executive Secretary, National Cancer

Institute Clinical Trials Review Working Group, National Cancer Institute, 6130 Executive Blvd., EPN, Rm. 540, Bethesda, MD 20892 (301-496-1718).

Individuals who plan to attend and need special assistance such as sign language interpretation or other reasonable accommodations should contact Dr. Cole in advance of the meeting.

Dated: October 28, 1996.

Paula N. Hayes,
Acting Committee Management Officer, NIH.
[FR Doc. 96-28266 Filed 11-1-96; 8:45 am]

BILLING CODE 4101-01-M

National Cancer Institute; Notice of Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Frederick Cancer Research and Development Center Advisory Committee.

The open portion of the meeting will be limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the contact person in advance of the meeting.

Committee Name: Frederick Cancer Research and Development Center Advisory Committee.

Date: December 17-18, 1996.

Place: Frederick Cancer Research and Development Center, Building 549, Executive Board Room.

Open: December 17—8:30 a.m.—11:00 a.m.

Agenda: Discussion of administrative matters such as future meetings, budget, and information items related to the operation of the NCI Frederick Cancer Research and Development Center.

Closed: December 17—11 a.m. to 5:00 p.m. December 18—8:30 a.m. to 5:00 p.m.

Agenda/Purpose: Discussion of previous site visit report and response for the Core Support Services with Science Applications International Corporation. The majority of the closed session will be devoted to a site review of the Molecular Virology and Carcinogenesis Laboratory under contract with ABL-Basic Research.

Contact Person: Cedric W. Long, Ph.D., Frederick Cancer Research and Development Center, P.O. Box B, Frederick, MD 21702, Telephone: 301-846-1108.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(2)(4) and 552b(c)(6), Title 5 U.S.C. The report and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the programs, disclosure of

which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: October 28, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96-28267 Filed 11-1-96; 8:45 am]

BILLING CODE 4140-01-M

National Cancer Institute; Notice of Meeting

Notice is hereby given of the meeting of the National Cancer Institute (NCI) Board of Scientific Advisors Prevention Program Review Working Group, December 17, 1996 at the Crystal Gateway Marriott, Arlington, VA.

The meeting will be closed to the public on December 17, 1996 from 8:30 AM to approximately 5:30 PM for discussion of confidential issues relating to review, discussion and evaluation of individual programs and projects conducted by the NCI Prevention Program. These discussions will reveal confidential trade secrets or commercial property such as patentable material, and personal information including consideration of personnel qualifications and performance, the competence of individual investigators and similar matters, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Information pertaining to the meeting may be obtained from Dr. Jack Gruber, Executive Secretary, National Cancer Institute Prevention Program Review Working Group, National Cancer Institute, 6130 Executive Blvd., EPN, Rm. 540, Bethesda, MD 20892 (301-496-9740).

Dated: October 28, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96-28268 Filed 11-1-96; 8:45 am]

BILLING CODE 4101-01-M

National Cancer Institutes; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Cancer Institute Special Emphasis Panel (SEP):

Name of SEP: Community Clinical Oncology Program.

Date: December 16-18, 1996.

Time: December 16—7 pm; December 17—18—8 am.

Place: Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Ray Bramhall, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 643, 6130 Executive Boulevard, MSC 7405, Bethesda, MD 20892-7405, Telephone: 301/496-3428.

Purpose/Agenda: This meeting will be devoted to the review, discussion, and evaluation of individual grant applications.

Name of SEP: Minority-Based Community Clinical Oncology Program.

Date: January 13-14, 1997.

Time: January 13—7 pm; January 14—8 am.

Place: Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Ray Bramhall, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 643, 6130 Executive Boulevard, MSC 7405, Bethesda, MD 20892-7405, Telephone: 301/496-3428.

Purpose/Agenda: This meeting will be devoted to the review, discussion, and evaluation of individual grant applications.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: October 28, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96-28269 Filed 11-1-96; 8:45 am]

BILLING CODE 4140-01-M

National Center for Human Genome Research; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following teleconference:

Agenda/Purpose: To review and evaluate grant applications and/or contract proposals.

Name of Committee: National Center for Human Genome Research Special Emphasis Panel 02.

Date: November 12, 1996.

Time: 12:00 pm.

Place: NIH, Building 38A, Room 609, 9000 Rockville Pike, Bethesda, Maryland.

Contact Person: Rudy Pozzatti, Ph.D., Office of Scientific Review, National Center for Human Genome Research, National Institutes of Health, Building 38A, Room 604, Bethesda, Maryland 20892, (301) 402-0838.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The applications and/or contract proposals, and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program No. 93.172, Human Genome Research)

Dated: October 29, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 96-28263 Filed 11-1-96; 8:45 am]

BILLING CODE 4140-01-M

National Heart, Lung, and Blood Institute; Notice of Meeting

Notice is hereby given of the meeting of the National Heart Attack Alert Program Coordinating Committee, sponsored by the National Heart, Lung, and Blood Institute on Tuesday, December 10, 1996, from 8:30 a.m. to 1:00 p.m. at the Bethesda Marriott Hotel, 5151 Pooks Hill Road, Bethesda, Maryland, 20814 (301) 897-9400.

The entire meeting is open to the public. The Coordinating Committee is meeting to define the priorities, activities, and needs of the participating groups in the National Heart Attack Alert Program. Attendance by the public will be limited to space available.

For detailed program information, agenda, list of participants, and meeting summary, contact: Ms. Mary Hand, Coordinator, National Heart Attack Alert Program, Office of Prevention, Education and Control; National heart, Lung, and Blood Institute; National Institutes of Health, Building 31, Room 4A-18, 31 Center Drive MSC 2480, Bethesda, Maryland 20892-2480 (301) 496-1051.

Dated: October 25, 1996.

Sheila E. Merritt,

Executive Officer, NHLBI.

[FR Doc. 96-28256 Filed 11-1-96; 8:45 am]

BILLING CODE 4140-01-M